Of the 460 patients randomized , 459 were included in the full analysis set ( glycopyrronium , n = 306 ; placebo , n = 154 ; mean age 64.7 years ; mean post-bronchodilator FEV1 : 50.8 % predicted ) ; 425 ( 92.4 % ) completed the study .